N/A N=21 Safety and Efficacy of High-Intensity Macrofocused Ultrasound for Solar Lentigo in Chinese Population
Solar Lentigo
Primary: Lab* Values of Lesional Area Using Dermoscopy and ImageJ — 68.850; 72.103; 73.147; 72.633 unitless
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=10 Study for the RevLite Laser System for Facial Solar Lentigines
Facial Solar Lentigines
Primary: Photographic Evaluation Using the Blinded Global Aesthetic Improvement Scale — 0; 1; 3; 3 Participants
N/A N=30 Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions
Pigmented Skin Lesion
Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations
N/A N=24 A Single-Center 2-Arm Study for Lentigines on the Hands
Lentigines
Primary: Percent Reduction in the Number of Hand Lentigines as Assessed by Blinded Reviewers.
N/A N=20 Laser Removal of Age (Sun) Spots on Hands
Solar Lentigines
Primary: Median VAS Improvement Score as Assessed by Blinded Physician Reviewers — 1.5 units on a scale — p=<0.0001
N/A N=50 A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy
Solar Lentigines
Primary: Solar Lentigines Count — 25.7; 26.0; 8.0; 11.0 Number of solar lentigines
N/A N=543 Virtual Sun Safe Workplaces Ph II (SSW Works)
Skin Cancer · Occupational Exposure
Primary: Change From Baseline Employee Sun Protection Practices at 1 Year — 3.55; 3.30; 3.71; 3.46 score on a scale
N/A N=31 An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light
Sun Damaged Skin
Primary: Number of TLR4 Signaling Pathway Analytes With a Significant Change in Expression From Baseline (Pre-solar Stimulated Light Exposure to 1 and 24 Hours Post Exposure)…
N/A N=11 Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin
Pre-cancerous Geriatric Skin
Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells
Phase 2 N=10 Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers
Aging · Skin Abnormalities
Primary: Change in Common Deletion (CD) Value in DNA of Skin Biopsy Sample — -84; 217 percent change
Phase 4 N=30 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
Actinic Keratosis
Primary: Percent Change in the Number of Actinic Keratoses — -75 % change in number of actinic keratoses
N/A N=90 Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna
Cancer · Lentigo Maligna
Primary: The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants — 27; 29 participants
N/A N=12 Fractionated 1927nm Laser for Hyperpigmentation in Fitzpatrick Skin Phototypes V and VI
Hyperpigmentation
Primary: Change in Spots - Front of Face (Part 1) — 53.60; 58.47; 56.44 spots
N/A N=27 Fractionated 1927nm Laser for Diffuse Pigmentation and Actinic Changes.
Skin Pigment
Primary: Change in Dyspigmentation Spots — 48.3; 46; 42.2; 42.5 Dyspigmentation Spots
Phase 3 N=20 Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion
Actinic Keratosis
Primary: Mean Number of Facial Actinic Keratoses at Week 12 — 2.70 Lesions
N/A N=20 Broad Band Light for the Treatment and Prevention of Senile Purpura
Senile Purpura · Bateman's Purpura
Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions
N/A N=32 A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal
Pigmented Skin Lesion of Suspected Benign Nature
Primary: Percentage of Participants With Change of Treated Lesions — 44; 44; 13 % of participants
Phase 2 N=14 Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL
Actinic Keratoses
Primary: Histological Lesion Clearance — 38.5; 69.2 percentage of complete histological clea
Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Phase 1 N=30 Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen
Skin Cancer
Primary: DNA Damage Level by Cyclobutane Pyrimidine Dimer (CPD) Measurement — 2.48; 2.18; 2.64; 1.14 Optical Density Units — p=0.003
Phase 2 N=16 Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Idiopathic Solar Urticaria
Primary: Assessment of the Minimal Urticaria Dose (MUD) on Each Test Site, After Application of the Test Products — 4.33; 3.93; 3.80; 3.67 Photodermatosis Protection Factor
Phase 1 N=59 Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment
Healthy
Primary: Frequency Distribution of Skin Irritation Scores — 39; 10; 3; 0 Scores on a scale
N/A N=37 A Photoxicity and Photoallergy Study of a Developmental Face Cream, Serum and Lotion
Skin Care
Primary: Percentage of Participants With Photo-initiated Potential Sensitization Reaction — 0; 0; 0; 0 Participants
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
Phase 2 N=32 Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin
Photoaged Skin
Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants
N/A N=41 Using Physical Tracking to Predict Sunburn
Prevention
Primary: Prevalence of Sun Protection Practices — 0.30; 0.43; 0.35; 0.41 proportion of practices/day
Phase 4 N=6 Can We Miss Pigmented Lesions in Psoriasis Patients?
Psoriasis · Melanoma · Non-melanoma Skin Cancer
Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants
N/A N=7 Study of a Novel Microlens Array Device for Skin Rejuvenation
Wrinkles · Scars
Primary: Physician's Global Assessment of Improvement — 2 score on a scale
Phase 2 N=52 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Mucosal Lentiginous Melanoma · Acral Lentiginous Malignant Melanoma
Primary: 2-month Progression-free Survival Rate — .52; .52 proportion of patients